Patents by Inventor Alexander Barrow

Alexander Barrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Siglec-15 antibodies and uses thereof
    Patent number: 9994636
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 12, 2018
    Assignees: MedImmune Limited, Cambridge Enterprise Limited
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF
    Publication number: 20170029503
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Application
    Filed: August 9, 2016
    Publication date: February 2, 2017
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Anti-Siglec-15 antibodies and uses thereof
    Patent number: 9447192
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: September 20, 2016
    Assignees: MEDIMMUNE LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF
    Publication number: 20150037356
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Application
    Filed: September 6, 2012
    Publication date: February 5, 2015
    Applicants: CAMBRIDGE ENTERPRISE LIMITED, MEDIMMUNE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor
    Patent number: 8642728
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: February 4, 2014
    Assignee: Cambridge Enterprise Ltd.
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
  • Modulation of the Activity and Differentiation of Cells Expressing the Osteoclast-Associated Receptor
    Publication number: 20130280273
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OSCAR expressing cells.
    Type: Application
    Filed: December 17, 2012
    Publication date: October 24, 2013
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
  • MODULATION OF THE ACTIVITY AND DIFFERENTIATION OF CELLS EXPRESSING THE OSTEOCLAST-ASSOCIATED RECEPTOR
    Publication number: 20120028903
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.
    Type: Application
    Filed: October 6, 2009
    Publication date: February 2, 2012
    Applicant: Cambridge Enterprise Limited
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale